Abstract
Selective androgen receptor modulators (SARMs) represent a novel class of drugs with tissue-specific agonistic and antagonistic properties, which are prohibited in sports from January 2008 according to the World Anti-Doping Agency. Preventive approaches to restrict the use of SARMs include early implementation of target analytes into doping control screening assays. Five model SARMs were synthesized, four of which are analogs to prostate-specific androgen receptor antagonists with a 5,6-dichloro-benzimidazole nucleus. The fifth SARM is a muscle-tissue specific agonist with a bicyclic hydantoin structure (BMS-564929). Dissociation pathways after negative electrospray ionization were studied using an LTQ-Orbitrap mass analyzer, and diagnostic product ions and common fragmentation patterns were employed to establish a screening procedure that target the intact SARMs as well as putative metabolic products. Sample preparation based on solid-phase extraction and subsequent LC–MS/MS measurement allowed for detection limits of 1–20 ng/mL, intra- and interday precisions of between 2.4 and 13.2% and between 6.5 and 24.2%, respectively. Recoveries varied from 89 to 106%, and tests for ion suppression or enhancement effects were negative for all analytes.
Similar content being viewed by others
References
Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT (2006) Nat Clin Pract Endocrinol Metab 2:146–159
Hengge UR (2003) AIDS Read 13:S15–S21
Moretti C, Frajese GV, Guccione L, Wannenes F, De Martino MU, Fabbri A, Frajese G (2005) J Endocrinol Invest 28:56–64
Gooren LJ, Bunck MC (2004) Drugs 64:1861–1891
Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD (1998) Biochem Biophys Res Commun 244:1–4
Mohler ML, Nair VA, Hwang DJ, Rakov IM, Patil R, Miller DD (2005) Exp Opin Ther Patents 15:1565–1585
Chen J, Kim J, Dalton JT (2005) Mol Interv 5:173–188
Negro-Vilar A (1999) J Clin Endocrinol Metab 84:3459–3462
Gao W, Dalton JT (2007) Drug Discov Today 12:241–248
Thevis M, Schänzer W (2007) Mini-Rev Med Chem 7:533–539
Omwancha J, Brown TR (2006) Curr Opin Investig Drugs 7:873–881
World Anti-Doping Agency (2008) The 2008 Prohibited List. http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf. Accessed 28 Nov 2007
Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W (2007) Rapid Commun Mass Spectom 21:3477–3486
Thevis M, Kamber M, Schänzer W (2006) Rapid Commun Mass Spectrom 20:870–876
Thevis M, Kohler M, Schänzer W (2007) Mass spectrometry of new growth promoting drugs: hydantoin-derived selective androgen receptor modulators and growth hormone secretagogues. In: Schänzer W, Geyer H, Gotzmann A, Mareck U (eds) Recent advances in doping analysis. Sport und Buch Strauß, Cologne (in press)
Ng RA, Guan J, Alford VC, Jr., Lanter JC, Allan GF, Sbriscia T, Lundeen SG, Sui Z (2007) Bioorg Med Chem Lett 17:955–958
Ng RA, Guan J, Alford VC Jr, Lanter JC, Allan GF, Sbriscia T, Linton O, Lundeen SG, Sui Z (2007) Bioorg Med Chem Lett 17:784–788
Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR, Jr., Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG (2006) Endocrinology 48:4–12
Sun C, Robl JA, Wang TC, Huang Y, Kuhns JE, Lupisella JA, Beehler BC, Golla R, Sleph PG, Seethala R, Fura A, Krystek SR, Jr., An Y, Malley MF, Sack JS, Salvati ME, Grover GJ, Ostrowski J, Hamann LG (2006) J Med Chem 49:7596–7599
Ng RA, Lanter JC, Alford VC, Allan GF, Sbriscia T, Lundeen SG, Sui Z (2007) Bioorg Med Chem Lett 17:1784–1787
Handelsman DJ (2004) Sci STKE 244:pe41
Catlin DH, Ahrens BD, Kucherova Y (2002) Rapid Commun Mass Spectrom 16:1273–1275
Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK (2004) Rapid Commun Mass Spectrom 18:1245–1249
Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH (2005) Rapid Commun Mass Spectrom 19:781–784
Thevis M, Schänzer W (2005) J Chromatogr Sci 43:22–31
ICH (2005) Validation of analytical procedures: text and methodology. http://www.ich.org/LOB/media/MEDIA417.pdf. Accessed 28 Jan 2008
Kromidas A (1999) Validierung in der Analytik. Wiley-VCH, Weinheim
Dams R, Huestis MA, Lambert WE, Murphy CM (2003) J Am Soc Mass Spectrom 14:1290–1294
Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Anal Chem 75:3019–3030
Thevis M, Geyer H, Mareck U, Schänzer W (2005) J Mass Spectrom 40:955–962
Mazzarino M, Botre F (2006) Rapid Comm Mass Spectrom 20:3465–3476
Kolmonen M, Leinonen A, Pelander A, Ojanpera I (2007) Anal Chim Acta 585:94–102
Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Nielen MW, Panderi I, Koupparis M (2007) Rapid Commun Mass Spectrom 21:2439–2446
Nielen MW, Bovee TF, van Engelen MC, Rutgers P, Hamers AR, van Rhijn JH, Hoogenboom LR (2006) Anal Chem 78:424–431
Jemal M, Ouyang Z, Zhao W, Zhu M, Wu WW (2003) Rapid Commun Mass Spectrom 17:2732–2740
Hakala KS, Kostiainen R, Ketola RA (2006) Rapid Commun Mass Spectrom 20:2081–2090
Li AC, Gohdes MA, Shou WZ (2007) Rapid Commun Mass Spectrom 21:1421–1430
Xia YQ, Miller JD, Bakhtiar R, Franklin RB, Liu DQ (2003) Rapid Commun Mass Spectrom 17:1137–1145
Thevis M, Kohler M, Schlörer N, Kamber M, Kuhn A, Linscheid MW, Schänzer W (2007) J Mass Spectrom. DOI 10.1002/jms.1364
Acknowledgments
The study was carried out with the support of the Federal Office of Sports, Magglingen, Switzerland, and the Manfred Donike Institute for Doping Analysis, Cologne, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thevis, M., Kohler, M., Thomas, A. et al. Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC–MS/MS. Anal Bioanal Chem 391, 251–261 (2008). https://doi.org/10.1007/s00216-008-1882-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-008-1882-6